News und Analysen
![BIOCORP unterzeichnet Vertriebsvereinbarung für Mallya-Technologie mit Roche Diabetes Care France](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
BIOCORP unterzeichnet Vertriebsvereinbarung für Mallya-Technologie mit Roche Diabetes Care France
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf die Entwicklung und Herstellung von Medizinprodukten und intelligenten
![BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery
![IMV Announces Annual and Special Meeting of Shareholders Voting Results](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
IMV Announces Annual and Special Meeting of Shareholders Voting Results
IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced the voting results from its annual and special meeting of shareholders held on
![LivaNova to Host Conference Call for Second Quarter 2020 Results](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova to Host Conference Call for Second Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m
![Pfizer Declares Third-Quarter 2020 Dividend](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Declares Third-Quarter 2020 Dividend
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of
![Bayer: Darum bricht die Aktie heute so stark ein!](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Bayer: Darum bricht die Aktie heute so stark ein!
Gestern gab es gleich zwei positive Nachrichten des Leverkusener Bayer-Konzerns (WKN: BAY001), die sich jedoch erst heute auf den Aktienkurs auswirken konnten. Denn leider kamen die News erst nach
![Premier Inc. Survey: Alternate Site Providers Report Increased PPE Needs but Face Challenges with Traditional Distribution Channels](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Premier Inc. Survey: Alternate Site Providers Report Increased PPE Needs but Face Challenges with Traditional Distribution Channels
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that the majority of alternate site providers, including senior living facilities
![THERANEXUS SECURES EUR 3.4 M LOAN UNDER THE FRENCH STATE GUARANTEE SCHEME (PGE) AND PROVIDES AN UPDATE ON ITS DEVELOPMENTS](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
THERANEXUS SECURES EUR 3.4 M LOAN UNDER THE FRENCH STATE GUARANTEE SCHEME (PGE) AND PROVIDES AN UPDATE ON ITS DEVELOPMENTS
- €6.5 M non-dilutive funding including PGE in Q2 2020
- Progress report on THN102 and BBDF-101 programs
Lyon, XX June 2020 – Theranexus, a biopharmaceutical company innovating in the treatment
![Sangamo Announces R&D Organization Changes](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.
Going forward, research and development will each be managed as separate functions
![Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a new multi-year, public-private
![Waters Extends the Capability and Power of its High-Resolution Mass Spectrometers](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Waters Extends the Capability and Power of its High-Resolution Mass Spectrometers
Waters Corporation (NYSE:WAT) announced today a new fragmentation technique and an imaging option for its high-resolution mass spectrometers giving research scientists working across a broad range
![Waters Introduces the New Arc High-Performance Liquid Chromatograph to Help Laboratories Meet Quality and Production Targets](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Waters Introduces the New Arc High-Performance Liquid Chromatograph to Help Laboratories Meet Quality and Production Targets
Waters Corporation (NYSE:WAT) today introduced the Waters™ Arc™ HPLC System, a new high-performance liquid chromatograph (HPLC) for routine testing in the pharmaceutical, food, academic and
![Illumina Accelerator Welcomes First Global Cohort of Genomics Startups](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs
![QIAGEN Announces Plans to Release Preliminary Q2 2020 Results](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
QIAGEN Announces Plans to Release Preliminary Q2 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it plans to provide in the first half of July 2020 an overview of preliminary results for the second quarter and first
![QIAGEN verkündet Pläne zur Veröffentlichung vorläufiger Ergebnisse für das zweite Quartal 2020](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
QIAGEN verkündet Pläne zur Veröffentlichung vorläufiger Ergebnisse für das zweite Quartal 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute Pläne bekannt, in der ersten Julihälfte 2020 einen Überblick über vorläufige Ergebnisse für das zweite Quartal und die erste Hälfte
![Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the
![Transgene’s and BioInvent’s BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Transgene’s and BioInvent’s BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (OMXS
![Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presents its broad viral vector expertise and their
![Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines:
-
Two studies (NCT04382326 and NCT04379713) of the
![Lantheus Completes Merger with Progenics](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lantheus Completes Merger with Progenics
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of
![Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
![IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus
IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious
![Premier Inc. Creates Oncology-Focused Purchasing Alliance with 20 Leading Cancer Providers to Source Branded Cancer Drugs](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Premier Inc. Creates Oncology-Focused Purchasing Alliance with 20 Leading Cancer Providers to Source Branded Cancer Drugs
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta®, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty
![Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec
![Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene